BLOOCELL®

BLOOCELL®, founded in 2016, is pioneering innovation in the fields of aerospace and medical/pharmaceutical industries through high-standard equipment manufacturing and automation systems. The company leverages advanced biotechnology for research on artificial tissues and organs, aiming to enhance future medical applications via successful in vitro and in vivo studies.

Located at the intersection of technology and healthcare, BLOOCELL® focuses on developing cutting-edge solutions like 3D bone tissue regeneration products. Utilizing polycaprolactone (PCL), a polymeric biomaterial approved by the U.S. Food and Drug Administration (FDA), the company offers innovative solutions for orthopedic and reconstructive surgeries, addressing the rising need for bone-related injury treatments.

The company's engineering team employs 3D printing technology to create customizable scaffolds, promising anatomy-specific adaptations. With a strong emphasis on long-term academic work and compliance with international quality standards, BLOOCELL® positions itself as a leader in the paradigm shift towards tissue engineering and regeneration, poised to attract investors seeking groundbreaking advancements in biotechnology.